Sutro Biopharma
STRO
113 hedge funds and large institutions have $280M invested in Sutro Biopharma in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 49 increasing their positions, 32 reducing their positions, and 12 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 32
16% more capital invested
Capital invested by funds: $241M → $280M (+$38.7M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.16% less ownership
Funds ownership: 9.82% → 9.66% (-0.16%)
1% less funds holding
Funds holding: 114 → 113 (-1)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$10.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.21M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
+$3.13M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$2.98M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$2.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BS
Banco Santander
Madrid,
Spain
|
-$2.08M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.86M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.63M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.62M |
| 5 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
-$1.31M |
STRO Hedge Fund Activity: Q3 2022 in Review
113 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q3 2022, worth a combined $280M — up 16% from $241M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of STRO and 11 opened new positions — a net loss of 1 holder — while 32 trimmed existing stakes and 49 added.
The largest buyer was Candriam SCA, adding an estimated $10.3M. The largest seller was Banco Santander, exiting entirely with an estimated $2.08M sold.
- 113 institutional investors held Sutro Biopharma (STRO) as of Q3 2022, down from 114 in Q2 2022.
- Funds reported $280M of Sutro Biopharma stock for Q3 2022, up 16% quarter-over-quarter.
- 11 funds opened new Sutro Biopharma positions in Q3 2022 and 12 closed out, a net change of -1 holder.
- The largest Sutro Biopharma buyer in Q3 2022 was Candriam SCA, an estimated $10.3M added.
- The largest Sutro Biopharma seller in Q3 2022 was Banco Santander, an estimated $2.08M sold.
Based on aggregated 13F filings for Q3 2022.